VBI Vaccines Announces Results of Annual General Meeting - Seite 2

 

90.17%

 

248,982

 

9.83%

Blaine H. McKee

 

2,333,881

 

92.11%

 

199,977

 

7.89%

Jeffrey R. Baxter

 

2,204,880

 

87.02%

 

328,977

 

12.98%

Nell Beattie

 

2,253,500

 

88.94%

 

280,358

 

11.06%

Each of the other matters put forward before the Shareholders for consideration and approval at the Meeting, as described in the Proxy Statement, were duly approved by the requisite number of votes. The Shareholders voted in favor of appointing EisnerAmper LLP as VBI's independent registered public accounting firm for the ensuing year and authorizing the audit committee of VBI's board of directors to fix its remuneration. The Shareholders also approved, each on an advisory basis, the frequency of holding an advisory vote on executive compensation every three years, and the compensation paid to the Company’s named executive officers as set forth in the Proxy Statement.

Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company's SEC and SEDAR filings.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. For more information, visit www.vbivaccines.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230623028843/en/

The VBI Vaccines Stock at the time of publication of the news with a fall of -7,05 % to 2,24EUR on Nasdaq stock exchange (23. Juni 2023, 21:50 Uhr).